Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01956812
Title Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer (PANCRIT-1)
Recruitment Terminated
Gender both
Phase Phase III
Variant Requirements No
Sponsors Immunomedics, Inc.
Indications

pancreatic adenocarcinoma

Therapies

Yttrium Y-90 clivatuzumab tetraxetan

Gemcitabine

Age Groups: adult
Covered Countries USA | FRA | ESP | CAN | BEL | AUT


No variant requirements are available.